Semaglutide improves biomarkers but fails to preserve memory in Alzheimer’s patients
Two major clinical trials evaluating the potential of the weight-loss drug semaglutide to treat Alzheimer’s disease have concluded without showing the desired clinical benefit. The manufacturer, Novo Nordisk, reported that…